Ghrelin Levels in Pancreatic Cancer Patients

Assessment of Plasma Ghrelin Levels in Patients With Pancreatic Cancer

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00225745

Enrollment

Registered

2005-09-26

Start date

2004-04-30

Completion date

2015-09-30

Last updated

2015-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic Cancer

Keywords

Ghrelin

Brief summary

The primary outcome measure for this study is plasma ghrelin level.

Detailed description

The primary outcome measure for this study is plasma ghrelin level, and the two primary comparison are: * Patients with cachexia versus patients without cachexia * Patients with cachexia versus healthy controls

Interventions

PROCEDUREBlood draw

One blood draw prior to first treatment

Study design

Observational model

CASE_CONTROL

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Histological or cytological proof of pancreatic adenocarcinoma * The control are will include healthy age-matched patients without cancer * The test arm will include patients with pancreatic cancer and they will divided into two groups: those with and without weight loss * Patients must have recovered from any major infections and/or surgical procedures

Exclusion criteria

* Patients with other serious medical illness like congestive heart failure, thyroid disease,liver disease or renal failure - conditions that will alter their nutritional state * Patients on appetite stimulant and those receiving total parenteral nutrition * Patients who have undergone gastrectomy or those who have gastric ulcers * Patients receiving active chemotherapy * No prior malignancy except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer or for which patient has been disease free for at least five years.

Design outcomes

Primary

Measure	Time frame
To evaluate plasma ghrelin levels in patients with pancreatic cancer and compare with age matched controls	prior to treatment

Secondary

Measure	Time frame
To investigate the role of ghrelin in pathophysiology of cancer cachexia	prior to treatment
To generate hypotheses for future studies and treatment based on the findings	prior to treatment

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026